Clopidogrel Versus Ticagrelor in Type-2 Diabetes

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Campus Bio-Medico University
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• type 2 diabetes mellitus

• stable coronary disease

• coronary revascularization with PCI at least 1 month prior to recruitment

Exclusion Criteria:

• acute coronary syndrome

• platelet count <70x109/l

• active bleeding or bleeding diathesis

• history of intracranial bleeding

• gastrointestinal bleeding <6 months

• cerebrovascular accident <3 months

• history of malignancy

• concomitant need for oral anticoagulant therapy

• severe liver disease or chronic renal failure (glomerular filtration rate <30 ml/min /1.73m2)